Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nuggets, pearls, and vignettes of master heart failure clinicians. Part 1--the medical history.

Congestive heart failure (Greenwich, Conn.)·2002
Same author

Nuggets, pearls, and vignettes of master heart failure clinicians. Part 2-the physical examination.

Congestive heart failure (Greenwich, Conn.)·2002
Same author

Histologic compaison of allograft myocardium between short- and long-term survivors of human cardiac transplantation.

The American journal of cardiology·2000
Same author

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.

Circulation·2000
Same author

Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients.

Journal of the American College of Cardiology·2000
Same author

The problem of ventricular dysrhythmias and sudden death mortality in heart failure: the impact of current therapy.

Cardiology·2000

Related Experiment Video

Updated: Jun 27, 2026

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
15:45

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice

Published on: February 10, 2013

Drugs five years later. Dobutamine.

C V Leier, D V Unverferth

    Annals of Internal Medicine
    |October 1, 1983
    PubMed
    Summary

    Dobutamine, a positive inotropic drug, enhances cardiac performance by stimulating beta-adrenergic receptors. It improves ventricular function in patients with cardiac decompensation without negatively impacting myocardial oxygen balance.

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine
    • Adrenergic Receptor Agonists

    Background:

    • Dobutamine is a synthetic catecholamine designed for short-term intravenous use.
    • Its mechanism involves selective stimulation of beta 1 adrenergic receptors, with minor effects on beta 2 and alpha 1 receptors.

    Purpose of the Study:

    • To evaluate the efficacy of dobutamine in improving cardiac performance in patients with ventricular dysfunction.
    • To assess the impact of dobutamine on myocardial oxygen supply and demand in patients with coronary artery disease.

    Main Methods:

    • Administration of dobutamine via parenteral route.
    • Monitoring of ventricular function, cardiac output, systemic blood pressure, organ perfusion, and ventricular filling pressures.
    • Assessment of myocardial oxygen supply and demand balance.

    More Related Videos

    Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
    07:41

    Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

    Published on: March 17, 2022

    Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
    08:07

    Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

    Published on: April 7, 2023

    Related Experiment Videos

    Last Updated: Jun 27, 2026

    Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
    15:45

    Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice

    Published on: February 10, 2013

    Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
    07:41

    Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

    Published on: March 17, 2022

    Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
    08:07

    Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

    Published on: April 7, 2023

    Main Results:

    • Dobutamine effectively improves ventricular function and cardiac performance in patients experiencing reduced stroke volume and cardiac output.
    • It can alleviate symptoms of cardiac decompensation in atherosclerotic coronary artery disease without compromising myocardial oxygen balance when used appropriately.
    • Dobutamine exhibits less vasopressor activity compared to norepinephrine and dopamine.

    Conclusions:

    • Dobutamine is a valuable therapeutic agent for enhancing cardiac output and improving organ perfusion in specific patient populations.
    • Its use is indicated for short-term management of ventricular dysfunction and cardiac decompensation.
    • Dobutamine should not be the primary treatment for severe hypotension and shock due to its limited vasopressor effects.